ERBB3 and esophageal adenocarcinoma: The aim of this study was to examine the immunohistochemical (IHC) expression of EGFR and HER3, as well as the occurrence of EGFR and KRAS mutations, in gastric and esophageal adenocarcinoma, with particular reference to their relationship with clinicopathological factors, HER2 expression, and OS.